Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Single-ascending-dose Study to Evaluate the Safety and Pharmacokinetics of MEDI0382 in Healthy Volunteers

Next Previous
Trial Profile

A Phase 1, Single-ascending-dose Study to Evaluate the Safety and Pharmacokinetics of MEDI0382 in Healthy Volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 26 Aug 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cotadutide (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; First in man
  • Sponsors MedImmune

Most Recent Events

  • 01 Aug 2021 Results assessing the safety and pharmacokinetics of cotadutide in phase 1 (n=32; 24 Japanese and 8 Chinese healthy adults) and phase 2 (n=61 Japanese adults) trials in overweight or obese participants of Asian descent with or without type 2 diabetes, published in the Diabetes, Obesity and Metabolism.
  • 12 Jun 2018 Results (n=48) published in the British Journal of Clinical Pharmacology.
  • 08 Sep 2015 Status changed from not yet recruiting to completed as per ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top